Chemistry:TAK-994
From HandWiki
Short description: Chemical compound
| Clinical data | |
|---|---|
| Routes of administration | Oral[1] |
| Drug class | Orexin receptor agonist |
TAK-994 is an orexin receptor agonist which is under development by Takeda for the treatment of narcolepsy.[2][3] It is a small-molecule and orally active compound and acts as a highly selective agonist of the orexin receptor 2 (OX2) (>700-fold selectivity over the orexin receptor 1 (OX1)).[2][3][4][1] TAK-994 is related to danavorexton (TAK-925).[5] The compound reached phase 2 clinical trials for narcolepsy.[6] However, clinical development was discontinued in October 2021 for safety reasons.[5][7][8][9][10] The chemical structure of TAK-994 has yet to be disclosed.[4]
See also
References
- ↑ 1.0 1.1 "How treatable is narcolepsy with current pharmacotherapy and what does the future hold?". Expert Opinion on Pharmacotherapy 22 (12): 1517–1520. August 2021. doi:10.1080/14656566.2021.1915987. PMID 33882765.
- ↑ 2.0 2.1 "0141 A Novel, Orally Available Orexin 2 Receptor-Selective Agonist, TAK-994, Shows Wake-Promoting Effects Following Chronic Dosing in an Orexin-Deficient Narcolepsy Mouse Model". Sleep 43 (Supplement 1): A56. April 2020. doi:10.1093/sleep/zsaa056.139. ISSN 0161-8105.
- ↑ 3.0 3.1 "Recently Approved and Upcoming Treatments for Narcolepsy". CNS Drugs 34 (1): 9–27. January 2020. doi:10.1007/s40263-019-00689-1. PMID 31953791.
- ↑ 4.0 4.1 "Discovery of Arylsulfonamides as Dual Orexin Receptor Agonists". Journal of Medicinal Chemistry 64 (12): 8806–8825. June 2021. doi:10.1021/acs.jmedchem.1c00841. PMID 34101446.
- ↑ 5.0 5.1 "Hypocretins (orexins): The ultimate translational neuropeptides". J Intern Med 291 (5): 533–556. January 2022. doi:10.1111/joim.13406. PMID 35043499.
- ↑ Clinical trial number NCT04096560 for "A Study of TAK-994 in Adults With Type 1 and Type 2 Narcolepsy" at ClinicalTrials.gov
- ↑ "Takeda Provides Update on TAK-994 Clinical Program". Business Wire. 5 October 2021. https://www.businesswire.com/news/home/20211005006237/en/Takeda-Provides-Update-on-TAK-994-Clinical-Program.
- ↑ "Takeda pauses TAK-994 clinical studies due to safety glitch". The Pharma Letter. 6 October 2021. https://www.thepharmaletter.com/article/takeda-pauses-tak-994-clinical-studies-due-to-safety-glitch.
- ↑ "Takeda Halts Phase II Studies For Key R&D Asset TAK-994 In Narcolepsy". Scrip. Informa Pharma Intelligence. 6 October 2021. https://scrip.pharmaintelligence.informa.com/SC145192/Takeda-Halts-Phase-II-Studies-For-Key-RD-Asset-TAK994-In-Narcolepsy.
- ↑ "Takeda flashes red light on 'breakthrough' narcolepsy drug after PhII trials turned up mysterious safety signal". Endpoints News. 6 October 2021. https://endpts.com/takeda-flashes-red-light-on-narcolepsy-drug-after-phii-trials-turned-up-mysterious-safety-signal/.
 |
